ubenimex has been researched along with Multiple Myeloma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, D; Jiang, Y; Kong, D; Li, X; Liu, J; Sun, S; Wang, X; Xu, T; Xu, W; Zhang, J; Zhang, L; Zhang, N; Zhao, J | 1 |
| Grujić, M; Renko, M | 1 |
2 other study(ies) available for ubenimex and Multiple Myeloma
| Article | Year |
|---|---|
Discovery of a Novel Ubenimex Derivative as a First-in-Class Dual CD13/Proteasome Inhibitor for the Treatment of Cancer.
Topics: Antiviral Agents; Enzyme Therapy; Humans; Multiple Myeloma; Proteasome Inhibitors | 2023 |
Aminopeptidase inhibitors bestatin and actinonin inhibit cell proliferation of myeloma cells predominantly by intracellular interactions.
Topics: Aminopeptidases; Buthionine Sulfoximine; Cell Division; Cell Membrane; Enzyme Inhibitors; Humans; Hydroxamic Acids; K562 Cells; Leucine; Multiple Myeloma; Substrate Specificity; U937 Cells | 2002 |